Vividion Therapeutics’ proteomics screening platform and small molecule library will be leveraged by the San Diego-based company and Roche to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.
Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.
